Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation

Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation

Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only treatment option with curative potential in patients with myelofibrosis (MF). The aim of our study was to evaluate the safety of splenectomy before alloHSCT in MF patients who failed to achieve significant spleen r...

Full description

Bibliographic Details
Main Authors: Maria Vladimirovna Barabanshikova, Igor Nikolaevich Zubarovsky, Vjacheslav Mikhailovich Savrasov, Andrey Jurjevich Korolkov, Vadim Valentinovich Baykov, Anna Vjacheslavovna Botina, Julia Jurjevna Vlasova, Ivan Sergeevich Moiseev, Elena Igorevna Darskaya, Elena Vladislavovna Morozova, Boris Vladimirovich Afanasyev
Format: Article
Language:English
Published: Elsevier 2019-09-01
Series:Hematology/Oncology and Stem Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1658387619300263

Internet

http://www.sciencedirect.com/science/article/pii/S1658387619300263

Similar Items